NBPF12 Inhibitors
Chemical inhibitors of NBPF12 play a crucial role in modulating the activity of this protein through various intracellular signaling pathways. Bisindolylmaleimide I and GF109203X, for instance, are known to selectively inhibit Protein Kinase C (PKC), a family of enzymes pivotal for numerous cellular functions, including the phosphorylation of proteins like NBPF12. The inhibition of PKC by these chemicals can lead to a reduced activation or improper localization of NBPF12 due to the lack of necessary phosphorylation events. Similarly, LY294002 and Wortmannin are inhibitors of phosphoinositide 3-kinase (PI3K), a key signaling molecule that regulates numerous cellular processes. By inhibiting PI3K, these compounds can disrupt downstream signaling pathways, leading to decreased activity of proteins potentially regulated by these pathways, such as NBPF12.
Moreover, the MAP kinase pathway, which includes several key signaling molecules, can be inhibited by compounds like SB203580, PD98059, U0126, and ZM336372, which target different kinases within the pathway. SB203580 specifically inhibits p38 MAPK, which can affect the function of NBPF12 if it is part of the p38 MAPK signaling network. PD98059 and U0126, both MEK inhibitors, prevent the activation of ERKs that could be crucial for NBPF12's activity. ZM336372 targets Raf-1 kinase, which also impacts the MAPK/ERK signaling. SP600125, targeting JNK, and PP2, an inhibitor of Src family tyrosine kinases, further demonstrate how diverse inhibitory mechanisms can converge on the modulation of NBPF12 activity. The inhibition of these kinases can lead to a decrease in NBPF12 function if it is part of signaling pathways that rely on tyrosine phosphorylation. Lastly, Y-27632, which inhibits the Rho-associated protein kinase (ROCK), can affect NBPF12 if its activity is regulated by pathways involving actin cytoskeleton dynamics. The interplay of these inhibitors underscores the complex regulatory environment that NBPF12 may be subjected to within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a potent and selective inhibitor of Protein Kinase C (PKC), which NBPF12 may rely on for phosphorylation events critical to its function. Inhibition of PKC can lead to reduced NBPF12 activity by preventing its phosphorylation-dependent activation or localization. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. Since PI3K signaling is crucial for many cell survival and growth pathways, inhibition by LY294002 can reduce the activity of downstream effectors, potentially including NBPF12, by suppressing PI3K-dependent signaling cascades. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. It blocks the p38 signaling pathway, which may be essential for the activity of NBPF12, especially if NBPF12 is involved in stress response or inflammation-related signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of the MAP kinase kinase (MEK), which is upstream of extracellular signal-regulated kinases (ERKs). Inhibiting MEK can prevent the activation of ERKs, potentially reducing the activity of NBPF12 if it is part of the ERK signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is implicated in controlling various cellular processes. Inhibition of JNK can lead to a decrease in NBPF12 activity if NBPF12 functions are dependent on JNK-mediated signaling pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor, functionally similar to PD98059, but chemically distinct. It blocks MEK1/2, which in turn may inhibit ERK signaling, thereby potentially reducing NBPF12 activity that is dependent on this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. By inhibiting PI3K, it can interrupt downstream signaling that may be crucial for the activity of NBPF12, leading to a decrease in its functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key regulator of cell growth and metabolism. By inhibiting mTOR, Rapamycin can alter the signaling pathways that NBPF12 may be involved in, especially if NBPF12 is associated with cellular growth processes. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. Inhibition of Src kinases can decrease NBPF12 activity by interrupting signaling pathways that are dependent on tyrosine phosphorylation events in which NBPF12 may participate. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of the Rho-associated protein kinase (ROCK). If NBPF12's activity is regulated by pathways involving actin cytoskeleton rearrangements mediated by ROCK, then inhibition by Y-27632 can lead to a reduction in NBPF12 activity. | ||||||